A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of DR-0201 in Patients With Select Autoimmune Rheumatic Diseases
Latest Information Update: 11 Nov 2024
At a glance
- Drugs DR-0201 (Primary)
- Indications Cutaneous lupus erythematosus; Dermatomyositis; Polymyositis; Sjogren's syndrome; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Dren Bio
- 23 Oct 2024 New trial record